Humanized Antibody Global Market Report 2025

The humanized antibody market size has grown rapidly in recent years. It will grow from $35.7 billion in 2024 to $39.7 billion in 2025 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to rising demand for targeted therapies, increasing prevalence of chronic diseases, growing adoption of monoclonal antibodies, expansion of the biosimilar market, and rising healthcare expenditure.

The humanized antibody market size is expected to see rapid growth in the next few years. It will grow to $64.33 billion in 2029 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to rising incidence of cancer, increasing prevalence of autoimmune diseases, growing demand for personalized medicine, expansion of the biosimilar market, and rising healthcare expenditure. Major trends in the forecast period include artificial intelligence and machine learning driven antibody discovery, cryo-electron microscopy enabled structure determination, next generation sequencing powered repertoire mining, single cell ribonucleic acid sequencing for target validation, and antibody drug conjugates with optimized linkers and payloads.

The growing prevalence of infectious diseases is expected to drive the growth of the humanized antibody market in the coming years. Infectious diseases are illnesses caused by pathogenic microorganisms, including bacteria, viruses, fungi, or parasites, which can be transmitted directly or indirectly between individuals. The incidence of infectious diseases is rising due to increased travel, which accelerates the spread of pathogens across borders. Humanized antibodies support infectious disease treatment by providing targeted immune responses, making them suitable for combating specific pathogens. They reduce the risk of immune rejection by closely resembling natural human antibodies, improving treatment safety and therapeutic effectiveness. For example, in February 2024, according to the UK Health Security Agency, a UK based government agency, tuberculosis cases in England rose to 4,850 in 2023, an increase of 10.7 percent from 4,380 cases in 2022. Therefore, the rising prevalence of infectious diseases is driving the expansion of the humanized antibody market.

Major companies in the humanized antibody market are developing innovative products such as humanized bispecific antibodies to expand labelable indications and provide stronger, more durable antitumor activity. Humanized bispecific antibodies are engineered to bind simultaneously to two different antigens or two distinct epitopes on the same antigen while being modified to closely resemble natural human antibodies. For example, on November 20, 2024, Jazz Pharmaceuticals plc, an Ireland based biopharmaceutical company, received accelerated approval from the U.S. Food and Drug Administration for Ziihera (zanidatamab-hrii) for previously treated, unresectable, or metastatic HER2-positive (IHC 3+) biliary tract cancer. It is a humanized, immunoglobulin G bispecific antibody targeting human epidermal growth factor receptor 2 (HER2) at two extracellular sites. It incorporates a proprietary mechanism that engages immune effector cells and directly induces apoptosis in cancer cells, enabling a targeted attack on malignant cells without prior immune activation.

In September 2024, Valerio Therapeutics S.A., a France based clinical-stage biotechnology company, acquired Emglev Therapeutics for an undisclosed amount. Through this acquisition, Valerio Therapeutics aims to strengthen its antibody discovery capabilities by integrating Emglev’s humanized single-domain antibody (sdAb) technology to accelerate the development of next-generation therapeutic candidates across multiple disease areas. Emglev Therapeutics is a France based biotechnology company specializing in humanized single-domain antibody development.

Major companies operating in the humanized antibody market are Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Sanofi S.A., Novartis AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Biogen Inc., Daiichi Sankyo Company Limited, UCB S.A., Genmab A/S, Xencor Inc., Zymeworks Inc., MacroGenics Inc.

North America was the largest region in the humanized antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in humanized antibody report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the humanized antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The humanized antibody market research report is one of a series of new reports that provides humanized antibody market statistics, including humanized antibody industry global market size, regional shares, competitors with a humanized antibody market share, detailed humanized antibody market segments, market trends and opportunities, and any further data you may need to thrive in the humanized antibody industry. This humanized antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Humanized antibody is a type of monoclonal antibody engineered to closely mimic human antibodies while maintaining the antigen binding specificity of the original non human antibody. It is produced by replacing most of the non human antibody’s protein sequences with corresponding human sequences, reducing the risk of immune reactions. It is widely used in research and therapy to target specific molecules with high precision and lower immunogenicity.

The main antibody types of humanized antibodies include humanized antibodies, chimeric antibodies, fully human antibodies, and murine antibodies. Humanized antibodies are laboratory engineered antibodies originally derived from non human species in which most of the molecular structure is replaced with human antibody components while retaining only the antigen binding regions necessary for target recognition. The various product types include monoclonal antibodies, polyclonal antibodies, and antibody drug conjugates, and they are applied in cancer, autoimmune diseases, infectious diseases, cardiovascular diseases, and others, serving end users such as hospitals, research institutes, diagnostic laboratories, and others.

The humanized antibody market consists of sales of humanized bispecific antibodies, humanized antibody fragments, humanized antibody libraries, and antibody humanization kits and reagents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.